keyword
https://read.qxmd.com/read/38616339/a-web-based-survey-on-the-occurrence-of-emotional-blunting-in-patients-with-major-depressive-disorder-in-japan-patient-perceptions-and-attitudes
#1
JOURNAL ARTICLE
Toshiaki Kikuchi, Jun-Ichi Iga, Masato Oosawa, Tatsuya Hoshino, Yoshiya Moriguchi, Miwa Izutsu
AIMS: To determine the prevalence and impact of emotional blunting (EB) in patients with major depressive disorder (MDD) in Japan, and identify treatment needs for EB using patients' perceptions and attitudes. METHODS: Eligible patients in Japan (aged 18-59 years) who reported a diagnosis of MDD and antidepressant medication use for >3 months were eligible to complete an online survey. The primary outcome was the prevalence of EB, self-reported using a validated screening question...
April 14, 2024: Neuropsychopharmacology Reports
https://read.qxmd.com/read/38615126/in-vivo-translocator-protein-in-females-with-autism-spectrum-disorder-a-pilot-study
#2
JOURNAL ARTICLE
Chieh-En Jane Tseng, Camila Canales, Rachel E Marcus, Anjali J Parmar, Baileigh G Hightower, Jennifer E Mullett, Meena M Makary, Alison U Tassone, Hannah K Saro, Paige Hickey Townsend, Kirstin Birtwell, Lisa Nowinski, Robyn P Thom, Michelle L Palumbo, Christopher Keary, Ciprian Catana, Christopher J McDougle, Jacob M Hooker, Nicole R Zürcher
Sex-based differences in the prevalence of autism spectrum disorder (ASD) are well-documented, with a male-to-female ratio of approximately 4:1. The clinical presentation of the core symptoms of ASD can also vary between sexes. Previously, positron emission tomography (PET) studies have identified alterations in the in vivo levels of translocator protein (TSPO)-a mitochondrial protein-in primarily or only male adults with ASD, with our group reporting lower TSPO relative to whole brain mean in males with ASD...
April 13, 2024: Neuropsychopharmacology
https://read.qxmd.com/read/38609530/rebound-activation-of-5-ht-neurons-following-ssri-discontinuation
#3
JOURNAL ARTICLE
Helen M Collins, L Sophie Gullino, Dersu Ozdemir, Caroline Lazarenco, Yulia Sudarikova, Elizabeth Daly, Fuencisla Pilar Cuéllar, Raquel Pinacho, David M Bannerman, Trevor Sharp
Cessation of therapy with a selective serotonin (5-HT) reuptake inhibitor (SSRI) is often associated with an early onset and disabling discontinuation syndrome, the mechanism of which is surprisingly little investigated. Here we determined the effect on 5-HT neurochemistry of discontinuation from the SSRI paroxetine. Paroxetine was administered repeatedly to mice (once daily, 12 days versus saline controls) and then either continued or discontinued for up to 5 days. Whereas brain tissue levels of 5-HT and/or its metabolite 5-HIAA tended to decrease during continuous paroxetine, levels increased above controls after discontinuation, notably in hippocampus...
April 12, 2024: Neuropsychopharmacology
https://read.qxmd.com/read/38605185/beyond-traditional-pharmacology-evaluating-phosphodiesterase-inhibitors-in-autism-spectrum-disorder
#4
JOURNAL ARTICLE
Fernando E Padovan-Neto, Ana Júlia de Oliveira Cerveira, Aline da Silva, Danilo Leandro Ribeiro
No abstract text is available yet for this article.
April 11, 2024: Neuropsychopharmacology
https://read.qxmd.com/read/38602109/can-calcitonin-gene-related-peptide-monoclonal-antibodies-ameliorate-writer-s-cramp-and-migraine
#5
Keisuke Suzuki, Shiho Suzuki, Hiroaki Fujita, Hirotaka Sakuramoto, Mukuto Shioda, Koichi Hirata
Recently, calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) have become available as a prophylactic treatment for migraine and have shown high efficacy and safety in clinical practice. CGRP mAbs have been reported to be effective not only for migraine but also for other comorbidities, such as psychiatric complications in patients with migraine. However, there are no reports examining the effect of CGRP mAbs on dystonia. We treated a patient with comorbid migraine and focal task-specific dystonia (writer's cramp) with a CGRP mAb (erenumab) because of an increase in monthly migraine days despite the addition of migraine prophylaxis...
April 11, 2024: Neuropsychopharmacology Reports
https://read.qxmd.com/read/38602056/decreased-oral-function-in-japanese-inpatients-with-schizophrenia
#6
JOURNAL ARTICLE
Yuichiro Watanabe, Masataka Otake, Shin Ono, Masaya Ootake, Kazuhiro Murakami, Koichiro Kumagai, Koji Matsuzawa, Hiroyuki Kasahara, Kazuhiro Hori, Toshiyuki Someya
AIM: Oral function in patients with schizophrenia has not been well-characterized. To address this, we performed a cross-sectional study of oral function in Japanese inpatients with schizophrenia. METHODS: We measured oral function, including occlusal force, tongue-lip motor function, tongue pressure, and masticatory function in 130 Japanese inpatients with schizophrenia. We then compared the frequency of clinical signs of oral hypofunction among 63 non-elderly and 67 elderly inpatients with schizophrenia, as well as data from 98 elderly control participants from a previous Japanese study...
April 11, 2024: Neuropsychopharmacology Reports
https://read.qxmd.com/read/38600711/outpatient-antipsychotic-use-and-severe-covid-19-avoiding-the-impact-of-age-in-a-real-world-data-study
#7
JOURNAL ARTICLE
Samuel Pintos-Rodríguez, Irene Visos-Varela, Almudena Rodríguez Fernández, Maruxa Zapata-Cachafeiro, María Piñeiro-Lamas, María Teresa Herdeiro, Rosa María García Álvarez, Adolfo Figueiras, Ángel Salgado-Barreira
BACKGROUND: The association between use of antipsychotics and COVID-19 outcomes is inconsistent, which may be linked to use of these drugs in age-related diseases. Furthermore, there is little evidence as regards their effect in the non-geriatric population . We aim to assess the association between antipsychotic use and risk of disease progression and hospitalisation due to COVID-19 among the general population, stratifying by age. METHODS: We conducted a population-based, multiple case-control study to assess: (1) risk of hospitalisation, with cases being patients with a PCR(+)test who required hospitalisation and controls being subjects without a PCR(+) test; and (2) risk of progression to hospitalisation, with cases being the same as those used in the hospitalisation substudy and controls being non-hospitalised PCR(+) patients...
April 11, 2024: International Journal of Neuropsychopharmacology
https://read.qxmd.com/read/38600154/am6527-a-neutral-cb1-receptor-antagonist-suppresses-opioid-taking-and-seeking-as-well-as-cocaine-seeking-in-rodents-without-aversive-effects
#8
JOURNAL ARTICLE
Omar Soler-Cedeño, Hannah Alton, Guo-Hua Bi, Emily Linz, Lipin Ji, Alexandros Makriyannis, Zheng-Xiong Xi
Preclinical research has demonstrated the efficacy of CB1 receptor (CB1R) antagonists in reducing drug-taking behavior. However, clinical trials with rimonabant, a CB1R antagonist with inverse agonist profile, failed due to severe adverse effects, such as depression and suicidality. As a result, efforts have shifted towards developing novel neutral CB1R antagonists without an inverse agonist profile for treating substance use disorders. Here, we assessed AM6527, a CB1R neutral antagonist, in addiction animal models...
April 10, 2024: Neuropsychopharmacology
https://read.qxmd.com/read/38598329/co-administration-of-probiotic-and-vitamin-d-significantly-improves-cognitive-function-in-schizophrenic-patients-a-double-blinded-randomized-controlled-trial
#9
JOURNAL ARTICLE
Aida Mohammadi, Gita Sadighi, Ali Nazeri Astaneh, Maryam Tajabadi-Ebrahimi, Tahereh Dejam
AIM: Manipulation of the intestinal microbiome and supplying vitamin D can attenuate psychiatric symptoms in schizophrenic patients. The current study tried to evaluate the effects of probiotic/vitamin D supplementation on the cognitive function and disease severity of schizophrenic patients. METHODS: In the present study, 70 patients (aged 18-65) with schizophrenia were recruited. Participants were randomly allocated to the placebo (n = 35) and intervention (probiotic supplements+400 IU vitamin D, n = 35) groups...
April 10, 2024: Neuropsychopharmacology Reports
https://read.qxmd.com/read/38588297/factor-structure-and-psychometric-properties-of-the-jordanian-version-of-the-depression-anxiety-stress-scale-dass-21
#10
JOURNAL ARTICLE
Khaled A Al-Dassean, Odeh S Murad
AIM: Early diagnosis of health conditions such as depression, anxiety, and stress, which have been recognized as global health issues, is essential for providing psychological support to people who experience negative emotions. Therefore, it is important to identify a reliable method for diagnosing depression, anxiety, and stress. To this end, this study investigated the factor structure and evaluated the psychometric properties of the Depression Anxiety Stress Scale-21 (DASS-21) in Jordan...
April 8, 2024: Neuropsychopharmacology Reports
https://read.qxmd.com/read/38588007/vortioxetine-induced-syndrome-of-inappropriate-secretion-of-antidiuretic-hormone-a-case-report
#11
Taro Sasaki, Yunosuke Shindo, Kota Kikuchi, Yasushi Kawamata, Norio Sugawara, Norio Yasui-Furukori
BACKGROUND: Vortioxetine, known for its efficacy in treating depression through its effects on various neurotransmitters, has not been previously reported to induce syndrome of inappropriate secretion of antidiuretic hormone (SIADH). CASE PRESENTATION: This case report describes a 74-year-old man with major depressive disorder who developed SIADH 1 week after starting treatment with vortioxetine. SIADH is characterized by symptoms such as headache, nausea, disorientation, and seizures, stemming from hyponatremia (123 mEq/L), without dehydration or edema...
April 8, 2024: Neuropsychopharmacology Reports
https://read.qxmd.com/read/38586960/global-perspectives-on-bipolar-disorder-treatment-in-depth-comparative-analysis-of-international-guidelines-for-medication-selection
#12
REVIEW
Ji Hyun Park, Kaveesha Fernando, Youngja Hwang Park, Esther O Park
BACKGROUND: Bipolar disorder, a chronic mental health condition characterised by fluctuations in mood, energy and functionality, affects millions of individuals worldwide. Its management requires a comprehensive approach, and, as such, treatment guidelines have a pivotal role in guiding clinicians to alleviate symptoms, prevent relapse and enhance overall patient well-being. However, the treatment landscape is far from homogenous, with significant variations existing across different countries...
April 8, 2024: BJPsych Open
https://read.qxmd.com/read/38582939/the-selective-d-3-receptor-antagonist-vk4-116-reverses-loss-of-insight-caused-by-self-administration-of-cocaine-in-rats
#13
JOURNAL ARTICLE
Marios C Panayi, Shohan Shetty, Micaela Porod, Lisette Bahena, Zheng-Xiong Xi, Amy Hauck Newman, Geoffrey Schoenbaum
Chronic psychostimulant use causes long-lasting changes to neural and cognitive function that persist after long periods of abstinence. As cocaine users transition from drug use to abstinence, a parallel transition from hyperactivity to hypoactivity has been found in orbitofrontal-striatal glucose metabolism and striatal D2 /D3 -receptor activity. Targeting these changes pharmacologically, using highly selective dopamine D3 -receptor (D3 R) antagonists and partial agonists, has shown promise in reducing drug-taking, and attenuating relapse in animal models of cocaine and opioid use disorder...
April 6, 2024: Neuropsychopharmacology
https://read.qxmd.com/read/38580806/author-correction-sex-differences-in-offspring-risk-and-resilience-following-11%C3%AE-hydroxylase-antagonism-in-a-rodent-model-of-maternal-immune-activation
#14
Julia Martz, Micah A Shelton, Laurel Geist, Marianne L Seney, Amanda C Kentner
No abstract text is available yet for this article.
April 5, 2024: Neuropsychopharmacology
https://read.qxmd.com/read/38579661/methods-for-neuroscience-drug-development-guidance-on-standardization-of-the-process-for-defining-clinical-outcome-strategies-in-clinical-trials
#15
JOURNAL ARTICLE
Silvia Zaragoza Domingo, Jordi Alonso, Montse Ferrer, Maria T Acosta, Larry Alphs, Peter Annas, Pavel Balabanov, Anna-Karin Berger, Kim I Bishop, Florence Butlen-Ducuing, Georg Dorffner, Chris Edgar, Manuel de Gracia Blanco, Brian Harel, John Harrison, William P Horan, Judith Jaeger, Jan Kottner, Amy Pinkham, Daniella Tinoco, Monika Vance, Christian Yavorsky
Neurosciences clinical trials continue to have notoriously high failure rates. Appropriate outcomes selection in early clinical trials is key to maximizing the likelihood of identifying new treatments in psychiatry and neurology. The field lacks good standards for designing outcome strategies, therefore The Outcomes Research Group was formed to develop and promote good practices in outcome selection. This article describes the first published guidance on the standardization of the process for clinical outcomes in neuroscience...
April 3, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/38577951/placebo-effects-are-small-on-average-in-the-7-5-co2-inhalational-model-of-generalised-anxiety
#16
JOURNAL ARTICLE
Nathan T M Huneke, Cosmina Cross, Harry A Fagan, Laura Molteni, Naomi Phillips, Matthew Garner, David S Baldwin
BACKGROUND: Anxiety disorders are highly prevalent and socio-economically costly. Novel pharmacological treatments for these disorders are needed as many patients do not respond to current agents or experience unwanted side-effects. However, a barrier to treatment development is the variable and large placebo response rate seen in trials of novel anxiolytics. Despite this, the mechanisms that drive placebo responses in anxiety disorders have been little investigated, possibly due to low availability of convenient experimental paradigms...
April 5, 2024: International Journal of Neuropsychopharmacology
https://read.qxmd.com/read/38573154/acute-dissociation-and-ketamine-s-antidepressant-and-anti-suicidal-ideation-effects-in-a-midazolam-controlled-trial
#17
JOURNAL ARTICLE
Sumra Sajid, Hanga C Galfalvy, John G Keilp, Ainsley K Burke, J John Mann, Michael F Grunebaum
OBJECTIVE: Explore relationships of acute dissociative effects of intravenous ketamine with change in depression and suicidal ideation and with plasma metabolite levels in a randomized, midazolam-controlled trial. METHOD: Data from a completed trial in suicidal, depressed participants (N=40) randomized to ketamine was used to examine relationships between ketamine treatment-emergent dissociative and psychotomimetic symptoms with pre/post-infusion changes in suicidal ideation and depression severity...
April 4, 2024: International Journal of Neuropsychopharmacology
https://read.qxmd.com/read/38570645/the-rostromedial-tegmental-nucleus-gates-fat-overconsumption-through-ventral-tegmental-area-output-in-male-rats
#18
JOURNAL ARTICLE
Florian Schoukroun, Katia Befort, Romain Bourdy
Excessive consumption of palatable foods that are rich in fats and sugars has contributed to the increasing prevalence of obesity worldwide. Similar to addictive drugs, such foods activate the brain's reward circuit, involving mesolimbic dopaminergic projections from the ventral tegmental area (VTA) to the nucleus accumbens (NAc) and the prefrontal cortex. Neuroadaptations occurring in this circuit are hypothesized to contribute to uncontrolled consumption of such foods, a common feature of most of eating disorders and obesity...
April 3, 2024: Neuropsychopharmacology
https://read.qxmd.com/read/38558544/severe-behavioral-and-psychological-symptoms-of-dementia-successfully-treated-at-home-with-a-blonanserin-transdermal-patch-a-case-report
#19
Junji Yamaguchi, Ryoichi Sadahiro, Takatoshi Hirayama, Saho Wada, Rika Nakahara, Hiromichi Matsuoka
AIM: Behavioral psychological symptoms of dementia (BPSD) are sometimes difficult to treat due to severe psychiatric symptoms such as delusions of poisoning and violent behavior. Moreover, in cases of parental neglect, the management of these psychiatric symptoms becomes more difficult. Therefore, home-visiting doctors sometimes have to manage patients with BPSD and severe psychiatric symptoms, and a new approach is needed. In this case report, the effect of blonanserin transdermal patch on these patients is to be highlighted...
April 1, 2024: Neuropsychopharmacology Reports
https://read.qxmd.com/read/38558385/availability-of-individual-proteins-for-quantitative-analysis-in-postmortem-brains-preserved-in-two-different-brain-banks
#20
JOURNAL ARTICLE
Atsuko Nagaoka, Mizuki Hino, Ryuta Izumi, Risa Shishido, Miki Ishibashi, Masataka Hatano, Makoto Sainouchi, Akiyoshi Kakita, Hiroaki Tomita, Yasuto Kunii
AIM: Postmortem brain research is necessary for elucidating the pathology of schizophrenia; an increasing number of studies require a combination of suitable tissue samples preserved at multiple brain banks. In this study, we examined whether a comparative study of protein expression levels can be conducted using postmortem brain samples preserved in different facilities. METHODS: We compared the demographic factors of postmortem brain samples preserved in two institutions and measured and compared the expression levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and glial fibrillary acidic protein (GFAP) in the prefrontal cortex and superior temporal gyrus...
April 1, 2024: Neuropsychopharmacology Reports
keyword
keyword
24969
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.